PortalPublikationenExternal beam radiation therapy improves survival in elderly...

External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA

Standard

External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. / Stolzenbach, Lara Franziska; Rosiello, Giuseppe; Deuker, Marina; Martin, Thomas; Knipper, Sophie; Tian, Zhe; Briganti, Alberto; Zorn, Kevin C; Saad, Fred; Chun, Felix K H; Graefen, Markus; Karakiewicz, Pierre I.

in: UROL ONCOL-SEMIN ORI, Jahrgang 39, Nr. 2, 02.2021, S. 131.e1-131.e7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stolzenbach, LF, Rosiello, G, Deuker, M, Martin, T, Knipper, S, Tian, Z, Briganti, A, Zorn, KC, Saad, F, Chun, FKH, Graefen, M & Karakiewicz, PI 2021, 'External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA', UROL ONCOL-SEMIN ORI, Jg. 39, Nr. 2, S. 131.e1-131.e7. https://doi.org/10.1016/j.urolonc.2020.10.011

APA

Stolzenbach, L. F., Rosiello, G., Deuker, M., Martin, T., Knipper, S., Tian, Z., Briganti, A., Zorn, K. C., Saad, F., Chun, F. K. H., Graefen, M., & Karakiewicz, P. I. (2021). External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. UROL ONCOL-SEMIN ORI, 39(2), 131.e1-131.e7. https://doi.org/10.1016/j.urolonc.2020.10.011

Vancouver

Stolzenbach LF, Rosiello G, Deuker M, Martin T, Knipper S, Tian Z et al. External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. UROL ONCOL-SEMIN ORI. 2021 Feb;39(2):131.e1-131.e7. https://doi.org/10.1016/j.urolonc.2020.10.011

Bibtex

@article{138603b67ad14e239692d14aa5ef68c0,
title = "External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA",
abstract = "BACKGROUND: It is unknown, whether metastatic prostate cancer (CaP) patients with intermediate life expectancy (5-10 years) should be considered for external beam radiation therapy (EBRT) to the prostate. We addressed this void.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 835 M1a or M1b CaP substaged patients with prostate-specific antigen (PSA) < 20 ng/ml and with intermediate life expectancy (LE) 5 to 10 years, treated with EBRT or no EBRT. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used.RESULTS: Overall, 179 (21.4%) patients received EBRT and 656 (78.6%) did not. EBRT rates increased from 13.9 to 23.8% (2004-2016; P= 0.04). After IPTW-adjustment, median OS was 45 vs. 35 months, in EBRT vs. no EBRT patients (P < 0.001). In IPTW-adjusted Cox-regression models, EBRT independently predicted lower overall mortality (hazard ratio [HR]: 0.7, CI 0.61-0.89; P= 0.001). After stratification according to M1 substages, EBRT was associated with lower overall mortality in M1a (HR: 0.2, CI 0.05-0.91; P= 0.03) and M1b (HR: 0.7, CI 0.55-0.88; P = 0.003) substages.CONCLUSION: EBRT was associated with lower mortality in metastatic CaP patients with low PSA and intermediate LE (5-10 years). In consequence, greater consideration for EBRT should be given in those patients. However, it is important to consider study limitations until clinical trials confirm the proposed benefit.",
author = "Stolzenbach, {Lara Franziska} and Giuseppe Rosiello and Marina Deuker and Thomas Martin and Sophie Knipper and Zhe Tian and Alberto Briganti and Zorn, {Kevin C} and Fred Saad and Chun, {Felix K H} and Markus Graefen and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2021",
month = feb,
doi = "10.1016/j.urolonc.2020.10.011",
language = "English",
volume = "39",
pages = "131.e1--131.e7",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA

AU - Stolzenbach, Lara Franziska

AU - Rosiello, Giuseppe

AU - Deuker, Marina

AU - Martin, Thomas

AU - Knipper, Sophie

AU - Tian, Zhe

AU - Briganti, Alberto

AU - Zorn, Kevin C

AU - Saad, Fred

AU - Chun, Felix K H

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2021/2

Y1 - 2021/2

N2 - BACKGROUND: It is unknown, whether metastatic prostate cancer (CaP) patients with intermediate life expectancy (5-10 years) should be considered for external beam radiation therapy (EBRT) to the prostate. We addressed this void.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 835 M1a or M1b CaP substaged patients with prostate-specific antigen (PSA) < 20 ng/ml and with intermediate life expectancy (LE) 5 to 10 years, treated with EBRT or no EBRT. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used.RESULTS: Overall, 179 (21.4%) patients received EBRT and 656 (78.6%) did not. EBRT rates increased from 13.9 to 23.8% (2004-2016; P= 0.04). After IPTW-adjustment, median OS was 45 vs. 35 months, in EBRT vs. no EBRT patients (P < 0.001). In IPTW-adjusted Cox-regression models, EBRT independently predicted lower overall mortality (hazard ratio [HR]: 0.7, CI 0.61-0.89; P= 0.001). After stratification according to M1 substages, EBRT was associated with lower overall mortality in M1a (HR: 0.2, CI 0.05-0.91; P= 0.03) and M1b (HR: 0.7, CI 0.55-0.88; P = 0.003) substages.CONCLUSION: EBRT was associated with lower mortality in metastatic CaP patients with low PSA and intermediate LE (5-10 years). In consequence, greater consideration for EBRT should be given in those patients. However, it is important to consider study limitations until clinical trials confirm the proposed benefit.

AB - BACKGROUND: It is unknown, whether metastatic prostate cancer (CaP) patients with intermediate life expectancy (5-10 years) should be considered for external beam radiation therapy (EBRT) to the prostate. We addressed this void.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 835 M1a or M1b CaP substaged patients with prostate-specific antigen (PSA) < 20 ng/ml and with intermediate life expectancy (LE) 5 to 10 years, treated with EBRT or no EBRT. Inverse probability of treatment-weighting (IPTW), Kaplan-Meier plots and Cox-regression models (CRMs) were used.RESULTS: Overall, 179 (21.4%) patients received EBRT and 656 (78.6%) did not. EBRT rates increased from 13.9 to 23.8% (2004-2016; P= 0.04). After IPTW-adjustment, median OS was 45 vs. 35 months, in EBRT vs. no EBRT patients (P < 0.001). In IPTW-adjusted Cox-regression models, EBRT independently predicted lower overall mortality (hazard ratio [HR]: 0.7, CI 0.61-0.89; P= 0.001). After stratification according to M1 substages, EBRT was associated with lower overall mortality in M1a (HR: 0.2, CI 0.05-0.91; P= 0.03) and M1b (HR: 0.7, CI 0.55-0.88; P = 0.003) substages.CONCLUSION: EBRT was associated with lower mortality in metastatic CaP patients with low PSA and intermediate LE (5-10 years). In consequence, greater consideration for EBRT should be given in those patients. However, it is important to consider study limitations until clinical trials confirm the proposed benefit.

U2 - 10.1016/j.urolonc.2020.10.011

DO - 10.1016/j.urolonc.2020.10.011

M3 - SCORING: Journal article

C2 - 33189532

VL - 39

SP - 131.e1-131.e7

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 2

ER -